Serum miR-629 is a novel molecular marker for diagnosis and the prognosis of pancreatic cancer

Abstract

Objective: Increasing evidence indicates that dysregulation of miRNAs is involved in tumor progression and development. We aimed to determine potential values of miR-629 as a serum diagnostic and prognostic biomarker in pancreatic cancer (PC).

Patients and methods: MiR-629 expression levels in PC tissues and serum were measured by quantitative Real-time reverse transcription-polymerase chain reaction (qRT-PCR). Receiver operating characteristic analysis (ROC) was utilized to assess the predictive power of serum miR-629 for PC. Then, the associations of serum miR-629 expression levels with clinicopathological features and prognosis were evaluated.

Results: We found that the expression levels of miR-629 were significantly upregulated in both PC tissues and serum in comparison with matched normal tissues and healthy controls, respectively. Importantly, serum miR-629 could efficiently screen PC patients from healthy controls (AUC=0.765). The diagnosis capability of serum miR-629 was significantly higher than that of CA19-9, and the combination of two molecules had higher diagnosis capacity. Higher expression of serum miR-629 in PC patients was associated with advanced TNM stage (p=0.000) and distant metastasis (p=0.003). Moreover, Kaplan-Meier analysis indicated that patients with high expression of serum miR-629 had significantly shorter overall survival (p=0.0022) and disease-free survival (p=0.0003) than the low expression group. Univariate and multivariate analysis showed that serum miR-629 was a significant and independent prognostic predictor for both overall survival and disease-free survival of PC patients.

Conclusions: This study suggested serum miR-629 may be a potential biomarker for the diagnosis and prognosis of PC.